首页> 外文OA文献 >PCV42 HOSPITALIZATION COSTS IN SOUTH KOREA FOR PATIENTS WITHOUT IDENTIFIED RISK FACTORS FOR BLEEDING WHO HAVE ACUTE CORONARY SYNDROMES WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL

【2h】

PCV42 HOSPITALIZATION COSTS IN SOUTH KOREA FOR PATIENTS WITHOUT IDENTIFIED RISK FACTORS FOR BLEEDING WHO HAVE ACUTE CORONARY SYNDROMES WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL

机译：在没有明确危险因素的患者中，韩国的PCV42医院住院费用是谁经急性冠状动脉综合征加经皮冠状动脉介入治疗进行冠状动脉介入治疗后才发现的。 TRITON-TIMI 38试验中的氯吡格雷

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Mahoney E; Wang K; Yang BM; Kim BRM; Lee HY; Chae IH; Kang SY;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. [J] . Mahoney EM, Wang K, Arnold S Circulation: An Official Journal of the American Heart Association . 2010,第1期

机译：普拉格雷与氯吡格雷在急性冠状动脉综合征和计划的经皮冠状动脉介入治疗中的成本效益：该试验的结果是通过优化普拉格雷-溶栓治疗心肌梗死TRITON-TIMI 38对血小板的抑制作用来评估治疗效果的改善。
2. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. [J] . ODonoghue M, Antman EM, Braunwald E Journal of the American College of Cardiology . 2009,第8期

机译：有或无糖蛋白IIb / IIIa抑制剂的普拉格雷在经皮介入治疗的急性冠状动脉综合征患者中的疗效和安全性：TRITON-TIMI 38（通过优化普拉格雷-溶栓治疗对血小板的抑制作用来评估心肌梗塞治疗效果的改善试验38 ）分析。
3. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: An analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38) [J] . KohliP., UdellJ.A., MurphyS.A., Journal of the American College of Cardiology . 2014,第3期

机译：普拉格雷与氯吡格雷治疗的急性冠脉综合征患者的阿司匹林剂量和临床结局：TRITON-TIMI 38研究的一项分析（尝试通过普拉格雷-溶栓治疗对心肌梗塞38进行血小板抑制优化来评估治疗效果的改善）
4. Expression of platelet endothelial cell adhesion molecule (PECAM-1) gene in the context of cardiovascular disease risk factors occurrence among patients with acute coronary syndrome ACS. [C] . Dabek J., GTogowska-Ligus J International Congress on Coronary Artery Disease . 2011

机译：急性冠状动脉综合征ACS患者心血管疾病危险因素患者中血小板内皮细胞粘附分子（PECAM-1）基因的表达。
5. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial [O] . Sabina A. Murphy, Elliott M. Antman, Stephen D. Wiviott, -1

机译：与TRITON-TIMI 38试验相关的急性冠脉综合征患者普拉格雷与氯吡格雷相比可减少复发性心血管事件
6. PCV64 INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL [O] . Mahoney EM, Wang K, Lei Y, 2008

机译：接受冠脉介入治疗的急性冠状动脉综合征患者行PCV64指数，随访和总住院费用的冠脉介入治疗。 TRITON-TIMI 38试验中的氯吡格雷

PCV42 HOSPITALIZATION COSTS IN SOUTH KOREA FOR PATIENTS WITHOUT IDENTIFIED RISK FACTORS FOR BLEEDING WHO HAVE ACUTE CORONARY SYNDROMES WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL

著录项

相似文献

相关主题

期刊订阅